Internal Medicine, Endocrinology, Diabetes, & Metabolism · Fremont, CA
NPI
1235163866
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
2557 Mowry Ave, Suite 12
Fremont, CA, 94538
Phone (510) 248-1550
Groups this clinician bills Medicare through
Medicare paid, 2024
$851K
53,590 services
Medicare patients, 2024
892
Average age 76
Drug cost, 2024
$3.2M
8,597 prescriptions
Company payments, 2025
$107
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Prasad Katta was code J3111 (injection, romosozumab-aqqg, 1 mg), 29,610 times for 30 patients. In total Prasad Katta billed 53,590 services in 31 codes, and Medicare paid $851K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-01-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 29,610 | 30 | $8.48 | $251K |
| J0897 Injection, denosumab, 1 mg | Office | 17,280 | 171 | $20.54 | $355K |
| 99214 Office E&M - Established | Office | 1,258 | 590 | $105.73 | $133K |
| 96372 Injection Administration | Office | 514 | 195 | $13.51 | $6,942 |
| 99213 Office E&M - Established | Office | 445 | 324 | $75.31 | $34K |
| 95251 Test - Miscellaneous | Office | 364 | 148 | $27.96 | $10K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 283 | 258 | $14.69 | $4,157 |
| 99231 Hospital E&M - Subsequent | Facility | 219 | 41 | $43.61 | $9,550 |
| 82962 Clinical Chemistry | Office | 112 | 92 | $3.21 | $360 |
| G0008 Administration of influenza virus vaccine | Office | 90 | 89 | $38.68 | $3,481 |
| 90662 Vaccine Product | Office | 87 | 86 | $81.02 | $7,049 |
| 99204 Office E&M - New | Office | 74 | 74 | $145.14 | $11K |
| 99203 Office E&M - New | Office | 65 | 65 | $89.90 | $5,843 |
| 99212 Office E&M - Established | Office | 63 | 60 | $47.73 | $3,007 |
| 99223 Hospital E&M - Initial | Facility | 34 | 31 | $146.22 | $4,971 |
By year: 2022 $697K for 41,353 services; 2023 $905K for 61,470 services; 2024 $851K for 53,590 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82962 Clinical Chemistry | 112 | 92 | $3.21 | $360 |
| 83036 Blood Count | 17 | 17 | $9.52 | $162 |
Medicare prescription drug claims, 2024
In 2024, the drug Prasad Katta prescribed most often to Medicare patients was Atorvastatin Calcium, with 579 prescriptions and refills. In total Prasad Katta wrote 8,597 Medicare prescriptions that cost $3.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Atorvastatin Calcium Generic | 579 | 1,642 | 178 | $6,545 |
| Metformin Hcl Generic | 550 | 1,510 | 174 | $5,395 |
| Levothyroxine Sodium Generic | 473 | 1,257 | 124 | $6,368 |
| Ozempic Semaglutide | 446 | 635 | 95 | $587K |
| Jardiance Empagliflozin | 402 | 758 | 97 | $418K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 298 | 658 | 106 | $42K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 276 | 650 | 109 | $34K |
| Humalog Kwikpen U-100 Insulin Lispro | 275 | 539 | 78 | $82K |
| Nateglinide Generic | 265 | 607 | 69 | $15K |
| Trulicity Dulaglutide | 232 | 362 | 56 | $342K |
| Pioglitazone Hcl Generic | 208 | 586 | 59 | $2,944 |
| Ezetimibe Generic | 197 | 537 | 58 | $8,383 |
| Losartan Potassium Generic | 175 | 519 | 56 | $1,538 |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | 169 | 344 | 55 | $86K |
| Glimepiride Generic | 164 | 474 | 54 | $1,718 |
Brand drugs: 3,533 claims; generic drugs: 4,400 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Prasad Katta $107 ($107 in general payments such as food, travel and fees) from 2 companies. The largest payer was Novo Nordisk Inc with $90.8.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.